Sat.Mar 06, 2021 - Fri.Mar 12, 2021

article thumbnail

Valneva and Pfizer start new Phase 2 study for Lyme disease vaccine candidate

Outsourcing Pharma

Valneva and Pfizer have initiated a Phase 2 study for their Lyme disease vaccine candidate: which is the only active Lyme disease vaccine in clinical development today.

Vaccines 138
article thumbnail

MPs slam £37bn NHS Test and Trace as UK endures third lockdown

pharmaphorum

There is no clear evidence that the UK’s £37 billion NHS Test and Trace programme (NHST&T) has an impact on the pandemic, according to a withering report from an influential committee of MPs. In its report the Public Accounts Committee (PAC) noted that Department of Health and Social Care justified the scale of the investment in part on the basis that an effective test and trace system would help avoid a second national lockdown.

136
136
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The drug Fenbendazole can make tumors sensitive to radiotherapy just like agents of chemotherapy

Pharma Mirror

Likewise, it was demonstrated by actualizing high throughput screening in-vitro framework that the drug fenbendazole is successful, not just against standard non-small cell lung cancer, NSCLC, yet in addition against the KRAS-mutant malignancy which seems, by all accounts, aggressive, barely accessible by chemotherapy and very normal (thirty percent of total cases of NSCLS) in people. [1] It became continually challenging in targeting KRAS transformation bearing tumors in view of the unclear con

article thumbnail

7 Best DRY MOUTH lozenges for saliva production

Druggist

The definition of dry mouth (medical term: xerostomia) is self-explanatory. Dry mouth may be experienced by anyone as one of the most common causes is dehydration. Many drugs can cause dry mouth. This side effect is sometimes associated with the whole class of medicines rather than a particular drug, making dry mouth management even more critical, as there may be little room for changing the medication.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Copado lands $96m in Series B funding to fuel life-sciences digital transformation

Outsourcing Pharma

The development technology firm plans to use the funds, sourced from a wide range of investors, to expand its dev-ops platform and expand its global reach.

73
article thumbnail

Patient involvement in trial design: looking to the future

pharmaphorum

COVID-19 has transformed the way we think about patient participation in trial design – but there are still many barriers to overcome in improving engagement. Speakers at the NIHR’s recent virtual event for the pharma industry discussed best practices for bringing patient insights into research. The pandemic has forced the industry to embrace virtual patient engagement to an extent that would have seemed unachievable little more than a year ago, but there is much more the industry needs to do to

More Trending

article thumbnail

Modafinil alternatives: BEST cognitive enhancers

Druggist

Modafinil (brand name Provigil) is one of the primary drugs used in the management of narcolepsy in the UK. Narcolepsy is a rare condition that affects sleep control and results in daytime sleepiness , often sudden and uncontrollable. The public’s interest in modafinil comes from the drug’s association with a class of medicines called ‘ smart drugs ‘, also called nootropics and cognitive enhancers.

FDA 90
article thumbnail

Survey reveals site team thoughts about advanced technologies

Outsourcing Pharma

The DT Clinical Trial Digital Tracker Survey indicates many trial professionals often are hesitant to dive fully into digital technology integration.

72
article thumbnail

Cambridge Sleep Sciences’ device is trialled in Parkinson’s

pharmaphorum

Sleep disturbances are a common feature for people with Parkinson’s disease, and a device developed to help people with insomnia is now being trialled to see if it can improve their sleep quality. . The SleepHub device – developed by Barkby group company Cambridge Sleep Sciences – is on the face of it a box and speakers that plays relaxing noises to help you fall asleep more easily, but is underpinned by a sound wave technology that its developer claims prompt the brain into the activity pattern

article thumbnail

NHS England breast cancer wait times are ‘deeply worrying’

Pharma Times

All waiting time targets for breast cancer were missed in January

52
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

5 WordPress Plugins to Save You Time

Mission-Driven Marketing Blog

Each day over 500 websites are built using WordPress. It is the most common content management system (CMS) in the world. With that popularity comes a wealth of documentation and plugins to solve almost any problem. In fact, the WordPress Plugin Directory currently features over 58,000 plugins.

article thumbnail

Report reveals gap between rare-disease drug spending, need

Outsourcing Pharma

The IQVIA and NORD study shows rare-disease treatments account for only 11% of new drug spending, but 80% of orphan products treat rare diseases alone.

55
article thumbnail

AI drug discovery firm Valence joins Parkinson’s disease push

pharmaphorum

Canada’s Valence Discovery has joined a University of Montreal-led project to try to find new drugs to treat the involuntary movement complications that can accompany treatments for Parkinson’s disease. . The go-to treatment for the five million people worldwide with Parkinson’s is levodopa, which replaces the activity of the dopamine neurotransmitter dopamine that gets depleted by the degeneration of nerve cells in the brain in the disease.

126
126
article thumbnail

New real-world evidence for Pfizer/BioNTech COVID-19 vaccine

Pharma Times

Evidence demonstrates lower incidence rates of COVID-19 in fully vaccinated individuals

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Avance Clinical Client Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19

Pharma Mirror

The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical congratulated Atossa Therapeutics on the announcement of their Phase 1 final results for the AT-301 nasal spray being developed for COVID-19. Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVI

52
article thumbnail

Thermo Fisher Scientific expands DTP trial service offerings

Outsourcing Pharma

The direct-to-patient service is designed to support trials and help to minimize trial length and costs, while boosting enrollment and participation rates.

52
article thumbnail

COVID cough app Hyfe launches in UK and Ireland

pharmaphorum

A smartphone app that uses artificial intelligence to assess the sound of coughing has been launched in the UK, and according to its developer could be an early warning system for COVID-19 and other diseases of the lung. . Hyfe uses acoustic technology to track users’ coughing habits, gauging factors like volume, frequency, amplitude and context, whilst running in the background on an iOS or Android device.

126
126
article thumbnail

CQC publishes new agreement with Equality and Human Rights Commission

Pharma Times

Agreement aims to safeguard rights of people receiving health and social care in England

52
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

CPhI Report forecasts explosion of contract services growth due to surging INDs and 75 FDA approvals by 2025

Pharma Mirror

A post-pandemic pharma report from CPhI predicts the next few years will deliver strong growth in pharma innovation, with oncology and rare diseases potentially the biggest beneficiaries of positive covid legacies – including accelerated development timelines, remote trials and new technologies in genetic and target screening. The report anticipates breakthroughs in multi-modal disease therapies within five years, mRNA platforms to transform many new non-infectious disease treatment options, and

FDA 52
article thumbnail

Setback for Novartis drug in advanced lung cancer trial

Outsourcing Pharma

Novartis reported today that a clinical trial of the drug, known as canakinumab, when combined with chemotherapy agent, docetaxel, failed to extend the lives of patients with advanced or metastatic non-small cell lung cancer when compared to just chemotherapy alone.

article thumbnail

New era of genomic medicine begins as UK approves Lilly’s Retsevmo

pharmaphorum

The UK regulator has authorised Eli Lilly’s targeted cancer drug Retsevmo for tumours with RET fusion positive lung cancers and thyroid cancers, which the company said could herald a new era of genomic medicine for the NHS. The UK Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional approval for Retsevmo (selpercatinib) as monotherapy for adults with advance RET fusion-positive non-small cell lung cancer requiring systemic therapy after previous immunotherapy and/or che

article thumbnail

Radiotherapy responses may be improved with targeted immunotherapy, study suggests

Pharma Times

Researchers studied inflammation in bowel tumour samples take before and after radiotherapy

51
article thumbnail

Syngenta and Botanical Solution Inc. (BSI) team up for a new botanical-based biofungicde rollout !

Pharma Mirror

Davis, CA: Botanical Solution Inc. (BSI) and Syngenta, two companies which are closely aligned in their commitment to innovation and sustainability in agriculture, announce that they have reached an agreement to commercialize BSI’s first product in Peru and Mexico. The two companies have already commercialized successfully the product in Chile under the trade name BotristopÒ.

52
article thumbnail

Connect 2 Cleanrooms builds temporary unit for NHS Wales COVID response

Outsourcing Pharma

The temporary medicines unit built for the agency's Central Intravenous Additive Service can produce up to 2,600 syringes weekly to meet growing demand.

52
article thumbnail

Life sciences must become cloud-first to seize the science of tomorrow

pharmaphorum

If the power of the life sciences industry to innovate and collaborate were ever in doubt, the speed at which vaccines for COVID-19 were discovered, developed, trialled, approved and manufactured have confirmed just how dynamic the industry can be. And that dynamism, innovation and collaboration are all qualities that the industry must continue to nurture as it faces the challenge of developing new medicines, treatments and services for the future.

Vaccines 111
article thumbnail

GSK to leverage the Cell and Gene Therapy Catapult’s facility in Stevenage

Pharma Times

British drugmaker to expand its clinical manufacturing capacity for cell and gene therapy

49
article thumbnail

Heart Failure Guideline Updates in 2021

Med Ed 101

There are a few important heart failure guideline updates in the works to the American College of Cardiology’s Heart Failure Guidelines, last published in 2013. Prior to the full guideline release, the organization recently printed their updated Expert Consensus Decision Pathway for treatment of patients with heart failure with reduced ejection fraction (HFrEF).

article thumbnail

ObvioHealth announces upgraded decentralized trial platform

Outsourcing Pharma

The companyâs technology facilitates remote patient monitoring and integrates with a wide range of wearable sensors for checking patient vital signs.

52
article thumbnail

Focus on Rare: the invisible burden of rare diseases

pharmaphorum

Emma Sutcliffe from NexGen Healthcare Communications looks at how patient insights can bring the invisible challenges of living with a rare condition into plain view. Over the past decade there has been considerable investment by pharma into research for rare disease as the patient voice and advocacy movement have done an outstanding job of raising awareness of the needs of the one in 17 who has a rare condition.

article thumbnail

Pharma, comms and patient group leaders join judging panel for Patient Partnership Index 2021

Pharma Times

Senior leaders from UK and European pharma have come together to judge the Patient Partnership Index 2021

49
article thumbnail

Lithium Toxicity Due To Thiazide Diuretic

Med Ed 101

It is critical to remember that lithium toxicity can result due to numerous possible drug interactions. Here’s a case scenario where lithium toxicity was caused by a thiazide diuretic. KE is a 44-year-old male with a history of bipolar disorder. Symptoms have been well controlled. He has recently been diagnosed with hypertension. His physician prescribed […].

40
article thumbnail

How GIFs Can Make a Difference in Patients’ Lives

Pharma Marketing Network

Ovarian cancer is a devastating disease, with the lowest survival rate of gynecologic cancers, striking and killing women of all ages and ethnicities. Yet there is a lack of education and awareness, as well as research funding. Unfortunately, women often ignore or misread symptoms until it’s too late. Could a pharmaceutical company’s awareness campaign help to make a difference?

article thumbnail

AI, big data and deep real-world evidence – the challenges and opportunities

pharmaphorum

Real-world evidence (RWE) is emerging as an important area of research to reveal, in real time, new insights and innovations and is accelerating the development of new and innovative therapies and treatments to improve patient outcomes. An important source of RWE has, until recently, been locked in the electronic health record (EHR). Now, artificial intelligence (AI) techniques such as natural language processing (NLP) and machine learning are helping clinicians unlock the data from this valuabl

110
110